Gujarat Themis Biosyn is currently trading at Rs. 45.00, up by 1.60 points or 3.69% from its previous closing of Rs. 43.40 on the BSE.The scrip opened at Rs. 44.95 and has touched a high and low of Rs. 45.00 and Rs. 44.95 respectively. So far 2150 shares were traded on the counter.The BSE group `X` stock of face value Rs. 5 has touched a 52 week high of Rs. 45.90 on 23-Sep-2019 and a 52 week low of Rs. 28.15 on 13-Feb-2019.Last one week high and low of the scrip stood at Rs. 45.90 and Rs. 42.00 respectively. The current market cap of the company is Rs. 63.05 crore.The promoters holding in the company stood at 74.99%, while Institutions and Non-Institutions held 0.03% and 24.97% respectively.Gujarat Themis Biosyn has implemented its new business model of manufacturing and supply of pharmaceutical products to various parties.Gujarat Themis Biosyn is a biotech and synthetic product manufacturing company. The company’s principal activity is to manufacture and distributes pharmaceuticals bulk drugs called rifampicin produced by fermentation process. The company`s products include preparations of active pharmaceutical ingredient rifampicin and lovastatin. The company exports its products to Europe and the United States.

Gujarat Themis Biosyn is currently trading at Rs. 44.35, up by 0.75 points or 1.72%, from its previous closing of Rs. 43.60 on the BSE.The scrip opened at Rs. 43.75 and has touched a high and low of Rs. 45.00 and Rs. 43.70 respectively. So far 2229 shares were traded on the counter.The BSE group `X` stock of face value Rs. 5 has touched a 52 week high of Rs. 45.90 on 23-Sep-2019 and a 52 week low of Rs. 28.15 on 13-Feb-2019.Last one week high and low of the scrip stood at Rs. 45.90 and Rs. 41.10 respectively. The current market cap of the company is Rs. 65.16 crore.The promoters holding in the company stood at 74.99%, while Institutions and Non-Institutions held 0.03% and 24.97% respectively.Gujarat Themis Biosyn has implemented its new business model of manufacturing and supply of pharmaceutical products to various parties.Gujarat Themis Biosyn is a biotech and synthetic product manufacturing company. The company’s principal activity is to manufacture and distributes pharmaceuticals bulk drugs called rifampicin produced by fermentation process. The company`s products include preparations of active pharmaceutical ingredient rifampicin and lovastatin. The company exports its products to Europe and the United States.

The company witnessed a 12.78% growth in the revenue at Rs. 117.07 millions for the quarter ended June 2019 as compared to Rs. 103.80 millions during the year-ago period.A slim rise of 5.29% was recorded in the Net profit for the quarter ended June 2019 to Rs. 14.13  millions  From Rs. 13.42 millions.Operating profit surged to 24.08 millions from the corresponding previous quarter of 20.27 millions. (Rs. in Million) Quarter ended Year to Date Year ended 201906 201806 % Var 201906 201806 % Var 201903 201803 % Var Sales 117.07 103.80 12.78 117.07 103.80 12.78 410.51 387.99 5.80 Other Income 6.94 1.03 573.79 6.94 1.03 573.79 22.14 1.65 1241.82 PBIDT 24.08 20.27 18.80 24.08 20.27 18.80 95.47 64.04 49.08 Interest 1.31 0.27 385.19 1.31 0.27 385.19 1.29 4.18 -69.14 PBDT 22.78 19.99 13.96 22.78 19.99 13.96 94.17 59.87 57.29 Depreciation 3.12 2.97 5.05 3.12 2.97 5.05 12.21 11.49 6.27 PBT 19.66 17.02 15.51 19.66 17.02 15.51 81.96 48.38 69.41 TAX 5.53 3.60 53.61 5.53 3.60 53.61 17.87 9.70 84.23 Deferred Tax 2.88 0.00 0.00 2.88 0.00 0.00 9.17 -0.60 -1628.33 PAT 14.13 13.42 5.29 14.13 13.42 5.29 64.09 38.68 65.69 Equity 72.64 72.64 0.00 72.64 72.64 0.00 72.64 72.64 0.00 PBIDTM(%) 20.58 19.52 5.43 20.57 19.53 5.33 23.25 16.51 40.86

The company`s total revenue for the quarter ended March 2019 saw a slight change in the total revenue, having registered a total revenue of Rs. 103.57 millions.The Net Profit of the company vaulted to 152.46% to Rs. 25.17  millions from Rs. 9.97 millions in the previous quarter.Operating profit for the quarter ended March 2019 rose to 35.14 millions as compared to 16.23 millions of corresponding quarter ended March 2018. (Rs. in Million) Quarter ended Year to Date Year ended 201903 201803 % Var 201903 201803 % Var 201903 201803 % Var Sales 103.57 99.54 4.05 410.51 387.99 5.80 410.51 387.99 5.80 Other Income 19.08 0.93 1951.61 22.14 1.65 1241.82 22.14 1.65 1241.82 PBIDT 35.14 16.23 116.51 95.47 64.04 49.08 95.47 64.04 49.08 Interest -0.03 1.07 -102.80 1.29 4.18 -69.14 1.29 4.18 -69.14 PBDT 35.17 15.17 131.84 94.17 59.87 57.29 94.17 59.87 57.29 Depreciation 3.55 2.92 21.58 12.21 11.49 6.27 12.21 11.49 6.27 PBT 31.62 12.25 158.12 81.96 48.38 69.41 81.96 48.38 69.41 TAX 6.45 2.28 182.89 17.87 9.70 84.23 17.87 9.70 84.23 Deferred Tax 9.25 -0.88 -1151.14 9.17 -0.60 -1628.33 9.17 -0.60 -1628.33 PAT 25.17 9.97 152.46 64.09 38.68 65.69 64.09 38.68 65.69 Equity 72.64 72.64 0.00 72.64 72.64 0.00 72.64 72.64 0.00 PBIDTM(%) 33.93 16.32 107.96 23.25 16.51 40.86 23.25 16.51 40.86

A slight decline in the revenue of Rs. 98.08 millions was seen for the December 2018 quarter as against Rs. 98.32 millions during year-ago period.Net profit stood at Rs. 12.14  millions  compared to Rs. 9.91 millions in the corresponding previous quarter,high by 22.50%.OP of the company witnessed a marginal growth to 20.83 millions from 16.10 millions in the same quarter last year. (Rs. in Million) Quarter ended Year to Date Year ended 201812 201712 % Var 201812 201712 % Var 201803 201703 % Var Sales 98.08 98.32 -0.24 306.94 288.45 6.41 387.99 356.92 8.71 Other Income 1.17 0.08 1362.50 3.06 0.73 319.18 1.65 3.65 -54.79 PBIDT 20.83 16.10 29.38 60.33 47.16 27.93 64.04 64.12 -0.12 Interest 0.61 0.49 24.49 1.32 3.12 -57.69 4.18 4.08 2.45 PBDT 20.22 15.61 29.53 59.00 44.06 33.91 59.87 60.05 -0.30 Depreciation 2.92 2.88 1.39 8.66 8.57 1.05 11.49 11.20 2.59 PBT 17.30 12.73 35.90 50.34 35.49 41.84 48.38 48.85 -0.96 TAX 5.17 2.82 83.33 11.42 7.42 53.91 9.70 5.07 91.32 Deferred Tax -0.08 0.44 -118.18 -0.08 0.28 -128.57 -0.60 0.53 -213.21 PAT 12.14 9.91 22.50 38.93 28.07 38.69 38.68 43.78 -11.65 Equity 72.64 72.64 0.00 72.64 72.64 0.00 72.64 72.64 0.00 PBIDTM(%) 21.24 16.38 29.70 19.66 16.35 20.22 16.51 17.97 -8.12

The revenue zoomed 9.49% to Rs. 103.80 millions for the quarter ended June 2018 as compared to Rs. 94.80 millions during the corresponding quarter last year.A comparatively good net profit growth of 46.83% to Rs. 13.42 millions was reported for the quarter ended June 2018 compared to Rs. 9.14 millions of previous same quarter.Operating profit for the quarter ended June 2018 rose to 20.27 millions as compared to 15.23 millions of corresponding quarter ended June 2017. (Rs. in Million) Quarter ended Year to Date Year ended 201806 201706 % Var 201806 201706 % Var 201803 201703 % Var Sales 103.80 94.80 9.49 103.80 94.80 9.49 387.99 356.92 8.71 Other Income 1.03 0.41 151.22 1.03 0.41 151.22 1.65 3.65 -54.79 PBIDT 20.27 15.23 33.09 20.27 15.23 33.09 64.04 64.12 -0.12 Interest 0.27 0.95 -71.58 0.27 0.95 -71.58 4.18 4.08 2.45 PBDT 19.99 14.30 39.79 19.99 14.30 39.79 59.87 60.05 -0.30 Depreciation 2.97 2.82 5.32 2.97 2.82 5.32 11.49 11.20 2.59 PBT 17.02 11.48 48.26 17.02 11.48 48.26 48.38 48.85 -0.96 TAX 3.60 2.34 53.85 3.60 2.34 53.85 9.70 5.07 91.32 Deferred Tax 0.00 -0.04 0.00 0.00 -0.04 0.00 -0.60 0.53 -213.21 PAT 13.42 9.14 46.83 13.42 9.14 46.83 38.68 43.78 -11.65 Equity 72.64 72.64 0.00 72.64 72.64 0.00 72.64 72.64 0.00 PBIDTM(%) 19.52 16.09 21.33 19.53 16.07 21.55 16.51 17.97 -8.12

The revenue declined to Rs. 99.54 millions for the quarter ended March 2018 as compared to Rs. 104.29 millions during the corresponding quarter last year.Net profit declined -17.47% to Rs. 9.97 millions from Rs. 12.08 millions.A decline of 16.23 millions was observed in the OP in the quarter ended March 2018 from 18.15 millions on QoQ basis. (Rs. in Million) Quarter ended Year to Date Year ended 201803 201703 % Var 201803 201703 % Var 201803 201703 % Var Sales 99.54 104.29 -4.55 387.99 356.92 8.71 387.99 356.92 8.71 Other Income 0.93 0.54 72.22 1.65 3.65 -54.79 1.65 3.65 -54.79 PBIDT 16.23 18.15 -10.58 64.04 64.12 -0.12 64.04 64.12 -0.12 Interest 1.07 1.63 -34.36 4.18 4.08 2.45 4.18 4.08 2.45 PBDT 15.17 16.52 -8.17 59.87 60.05 -0.30 59.87 60.05 -0.30 Depreciation 2.92 3.09 -5.50 11.49 11.20 2.59 11.49 11.20 2.59 PBT 12.25 13.43 -8.79 48.38 48.85 -0.96 48.38 48.85 -0.96 TAX 2.28 1.35 68.89 9.70 5.07 91.32 9.70 5.07 91.32 Deferred Tax -0.88 0.30 -393.33 -0.60 0.53 -213.21 -0.60 0.53 -213.21 PAT 9.97 12.08 -17.47 38.68 43.78 -11.65 38.68 43.78 -11.65 Equity 72.64 72.64 0.00 72.64 72.64 0.00 72.64 72.64 0.00 PBIDTM(%) 16.32 17.40 -6.25 16.51 17.97 -8.12 16.51 17.97 -8.12

The company witnessed a 15.62% growth in the revenue at Rs. 98.32 millions for the quarter ended December 2017 as compared to Rs. 85.04 millions during the year-ago period.The Company`s Net profit for the December 2017 quarter have declined marginally to Rs. 9.91  millions as against Rs. 10.78 millions reported during the corresponding quarter ended.OP of the company witnessed a marginal growth to 16.09 millions from 15.65 millions in the same quarter last year. (Rs. in Million) Quarter ended Year to Date Year ended 201712 201612 % Var 201712 201612 % Var 201703 201603 % Var Sales 98.32 85.04 15.62 288.45 252.64 14.17 356.92 326.25 9.40 Other Income 0.08 0.67 -88.06 0.73 3.11 -76.53 1.69 1.70 -0.59 PBIDT 16.09 15.65 2.81 47.16 45.99 2.54 61.73 62.05 -0.52 Interest 0.49 0.88 -44.32 3.12 2.46 26.83 3.53 3.77 -6.37 PBDT 15.60 14.77 5.62 44.04 43.53 1.17 58.20 58.28 -0.14 Depreciation 2.88 2.71 6.27 8.57 8.11 5.67 11.20 11.99 -6.59 PBT 12.73 12.06 5.56 35.50 35.43 0.20 47.00 46.29 1.53 TAX 2.82 1.28 120.31 7.42 3.74 98.40 4.55 0.00 0.00 Deferred Tax 0.44 0.05 780.00 0.28 0.23 21.74 0.00 0.00 0.00 PAT 9.91 10.78 -8.07 28.07 31.69 -11.42 42.45 46.29 -8.30 Equity 72.64 72.64 0.00 72.64 72.64 0.00 72.64 72.64 0.00 PBIDTM(%) 16.38 18.40 -11.02 16.35 18.20 -10.19 17.30 19.02 -9.06

Gujarat Themis Biosyn has informed that the meeting of the Board of Directors of the Company is scheduled to be held on February 14, 2017, to consider and approve the unaudited Financial Results for the quarter/nine months ended on December 31, 2016. Further, the Trading Window in respect of the Company’s Securities shall remain closed for all Directors/Officer/Designated Employees of the Company from the opening of the trading hours on February 07, 2017 till the completion of 48 hours after conclusion of the Board meeting i.e. till February 16, 2017The above information is a part of company’s filings submitted to BSE.

Gujarat Themis Biosyn has informed about Quarterly Statement on Investor Complaints / Grievances Redressal Mechanism for the Quarter ended December 31, 2016, under Regulation 13(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.The above information is a part of company’s filings submitted to BSE.

Gujarat Themis Biosyn has informed that the Company has received resignation letter from Dharmisthaben Raval dated December 22, 2016 with immediate effect due to personal reasons. Dharmisthaben N. Raval was associated with the Company as an Independent Woman Director on the Board.The above information is a part of company’s filings submitted to BSE.

Gujarat Themis Biosyn has informed that the 35th Annual General Meeting (AGM) of the Company was held on September 14, 2016.The above information is a part of company’s filings submitted to BSE.